LeMaitre Vascular (NASDAQ:LMAT) Rating Lowered to “Hold” at Zacks Research

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other research analysts have also weighed in on LMAT. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, June 30th. Citizens Jmp raised their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Barrington Research reiterated an “outperform” rating and issued a $120.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Wells Fargo & Company boosted their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Freedom Capital raised LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $112.60.

LeMaitre Vascular Trading Up 1.9%

Shares of LeMaitre Vascular stock opened at $105.70 on Monday. The stock has a market capitalization of $2.42 billion, a P/E ratio of 39.00, a P/E/G ratio of 2.88 and a beta of 0.52. LeMaitre Vascular has a 52-week low of $79.00 and a 52-week high of $118.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The stock’s 50-day simple moving average is $98.45 and its 200 day simple moving average is $97.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same quarter last year, the company earned $0.48 earnings per share. The company’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, research analysts anticipate that LeMaitre Vascular will post 3 EPS for the current year.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,928 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider directly owned 3,749 shares in the company, valued at $401,143. This represents a 43.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 27,881 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the sale, the chief executive officer directly owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LMAT. Sound Income Strategies LLC raised its stake in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC bought a new position in shares of LeMaitre Vascular in the 1st quarter worth $32,000. Geneos Wealth Management Inc. raised its position in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular during the 2nd quarter worth $47,000. Finally, GAMMA Investing LLC lifted its holdings in shares of LeMaitre Vascular by 32.7% during the 4th quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 179 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.